WO2007131390A1 - Milieu de contraste radiotransparent formé d'une matrice aqueuse pour la tomographie par ordinateur du tractus gastrointestinal et procédé de préparation de ce dernier - Google Patents
Milieu de contraste radiotransparent formé d'une matrice aqueuse pour la tomographie par ordinateur du tractus gastrointestinal et procédé de préparation de ce dernier Download PDFInfo
- Publication number
- WO2007131390A1 WO2007131390A1 PCT/CN2006/001063 CN2006001063W WO2007131390A1 WO 2007131390 A1 WO2007131390 A1 WO 2007131390A1 CN 2006001063 W CN2006001063 W CN 2006001063W WO 2007131390 A1 WO2007131390 A1 WO 2007131390A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- contrast agent
- density
- negative contrast
- hydrogel
- matrix
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
- A61K49/0457—Semi-solid forms, ointments, gels, hydrogels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to a contrast agent and a method of preparing the same, and more particularly to an aqueous matrix digestive tract CT negative contrast agent and a preparation method thereof.
- the invention belongs to the field of biomedical technology. Background technique
- Gastrointestinal diseases especially colon cancer
- X-ray tomography is widely used in clinical imaging for the diagnosis of digestive diseases.
- CT X-ray tomography
- its sub-second scanning speed has basically solved the artifacts caused by respiratory movement and intestinal peristalsis, so it plays a role in the diagnosis of intestinal lesions, especially colonic lesions. More and more important role.
- water and air are generally used as intestine filling agents to ensure the filling of the lumens, so as to fully display the anatomical relationships, increase the detection rate of small lesions, and reduce the false positive rate.
- the use of 3D image reconstruction technology for simulation endoscopic image analysis further improves the specificity and sensitivity of the diagnosis of digestive tract diseases.
- existing CT imaging techniques cannot be timely and accurately diagnosed.
- existing intestinal contrast agents are positive (CT high density) and neutral (CT density close to water) contrast agents.
- Positive contrast agents often mask small lesions, and high-density intra-field contrast agents interfere with the enhancement of the intestinal wall; the density difference between the neutral contrast agent and the intestinal wall is too small, and it is difficult to distinguish the intestinal wall, lesions and intestines in the case of poor filling.
- the structure of the cavity and other structures has a high rate of missed diagnosis, and VR and VE reconstruction cannot be achieved. Therefore, it is very important to develop a CT-negative (low-density) contrast agent that can effectively improve the imaging quality of the intestinal wall and facilitate the reconstruction of three-dimensional simulated endoscopic images.
- the intestinal contrast agent can simultaneously achieve a good filling of the intestinal lumen, optimal display of the intestinal wall, and the three-dimensional simulation processing of the image.
- the CT density of the first three preparations is about 10 to -80 HU (Hounsfield Unit), which can not effectively improve the resolution of the intestinal wall, and can not meet the requirements of 3D simulation image reconstruction; Paraffin oil CT dense The degree is about 100HU. After perfusion, the resolution of the intestinal wall can be effectively improved, and image reconstruction can be performed, but it has a strong diarrhea effect, so it is not suitable for clinical application.
- Three-dimensional simulation using air enema with a CT density of about 1000 HU is highly sensitive and specific for observing lesions in the intestinal cavity such as polyps and tumors.
- the intestinal wall is poorly displayed on the CT slice, and the intestinal wall shown is often thinner than the normal intestinal wall, and the pathological changes in the intestinal wall cannot be accurately reflected.
- the present invention is directed to the deficiencies of the existing intestinal CT contrast agents described in the background art, and the need for clinical diagnosis, and proposes an aqueous matrix digestive tract CT negative contrast agent and a preparation method thereof.
- the suspension-type negative contrast agent is safe, non-toxic and stable; it does not contain paraffin oil, vegetable oil and other oils and diarrhea components such as mannitol.
- the contrast agent can effectively fill the intestinal lumen, clearly display the intestinal wall, and simultaneously perform three-dimensional image analysis such as simulated endoscopy, thereby greatly improving the sensitivity and specificity of CT for early diagnosis of intestinal wall and intestinal lumen.
- Diagnosis and treatment provide a reliable imaging basis.
- the contrast agent is convenient to use, and the patient only needs to perform a bowel preparation to perform a relatively complete imaging series examination, which reduces the inconvenience caused by the preparation of the bowel and saves the inspection cost.
- the CT-negative contrast agent of the digestive tract of the aqueous substrate of the present invention is a suspension preparation formed by suspending micro-nano particles of a low-density substance in a hydrogel matrix, and the components and weight percentages thereof are: water Gel matrix 0. 01-1%, low density material micro-nanoparticle 5 - 50%, stabilizer 0. 1 - 5%, the rest is deionized water.
- the micro-nanoparticles of the low-density material are low-density gas microbubbles or/and low-density solid particles.
- the contrast agent of the invention has a CT density value of between 30 HU and 500 HU. After filling the intestine, the CT image density of the intestinal lumen is significantly lower than that of the intestinal wall, and there is no uneven distribution of density.
- the contrast agent of the present invention is prepared by dispersing or swelling a viscous solution or semi-solid substance formed in water by a natural or artificially synthesized hydrophilic polymer, and has the ability to fill the intestine while having good fluidity.
- the present invention also provides a method for preparing a digestive tract CT negative contrast agent of the above aqueous substrate, specifically: firstly dispersing or swelling a natural or artificially synthesized hydrophilic polymer in water to form a hydrogel matrix. Then, stabilizers are added, low-density micro-nano particles are added or prepared, dispersed, formed into a suspension formulation in a hydrogel matrix, and the stability and fluidity of the suspension are adjusted by adjusting the viscosity of the stabilizer and the hydrogel. , get a consistent, stable, fluidity, negative contrast agent for intestinal CT imaging studies.
- the low-density material used in the invention has a density less than water, a CT value of between 50 HU and 1000 HU, and is easily dispersed but insoluble in water, including various gas microbubbles, polyethylene or polypropylene particles conforming to medical requirements, or the like.
- the concentration of the micro-nanoparticles of the low-density material in the suspension can be adjusted according to the needs of the application of the preparation, generally between 5 and 50%.
- Low-density gas microbubbles refer to microbubbles at 25 ° C and 1 atm.
- the gases contained include air, carbon dioxide, nitrogen, oxygen, fluoroalkanes, chlorofluoroalkanes, thiofluoroalkanes, inert gases including helium, neon, argon, helium, neon, and combinations thereof.
- the volume of microbubbles in the hydrogel matrix is 5-50% at 1 atmosphere.
- Low-density solid particles refer to water-insoluble polymer particles with a CT value of 50 HU to 1000 HU at 25 ° (:, 1 atm.), including polyolefin, polyethylene, polypropylene and their mixed polymers. And a combination, the particle size is between 0. 05- lOOOMm, and its concentration in the hydrogel matrix is 5-50%.
- the hydrogel matrix used in the present invention may be any hydrophilic natural and artificial polymers recognized in the art, such as cellulose and its derivatives, chitosan and its derivatives, agar, gelatin, gum arabic, western yellow. Silicone, sodium polyacrylate and mixtures of these. Hydrogels The concentration is 0. 01-1%; in order to improve the stability of the suspension and the uniformity in the low-density material 3 ⁇ 4 suspension, a certain amount of stabilizer is also added to the suspension.
- the stabilizer used in the present invention is selected from the group consisting of proteins, glucose caprolactone, various ionic and nonionic surfactants, lipids, amphiphilic polymers, and mixtures thereof, such as dodecyl sulfonic acid. 1-5.
- the total concentration of the suspension stabilizer in the suspension is 0. 1 - 5
- the total concentration of the suspension stabilizer in the suspension is 0. 1 - 5 %.
- Method one is in a hydrogel matrix containing a certain concentration of stabilizer.
- the gas such as air, nitrogen and inert gas, is introduced into the gas to directly generate the gas microbubbles, and the stabilizer is used to further disperse and stabilize the microbubbles.
- the second method is to use a hydrogel matrix containing a certain concentration of stabilizer, and to add a low-boiling liquid such as a fluoroanthracene hydrocarbon, a chlorofluorohydrocarbon or a thiofluoroalkane, and a mixture thereof at a temperature lower than the phase transition temperature.
- a low-boiling liquid such as a fluoroanthracene hydrocarbon, a chlorofluorohydrocarbon or a thiofluoroalkane, and a mixture thereof at a temperature lower than the phase transition temperature.
- Preparation of a low-density solid particle suspension in a hydrogel matrix can be achieved by any of the following three methods: Method one is to take a medical polyethylene or polypropylene material particle and pre-freeze it into a jet mill to carry out Ultrafine pulverization, obtaining fine particles having a diameter of 0.05 - ⁇ , further mixing with a stabilizer, dispersing into a hydrogel matrix, and preparing a suspension of low-density solid particles having different CT density values; The medical polyethylene or polypropylene material particles are firstly mixed with the stabilizer and then pre-frozen, and then added to the jet mill to be ultra-finely pulverized to obtain fine particles having a surface of 0. 05- lOOOMm and having hydrophilic surface.
- Method 3 Disperse into a hydrogel matrix to form a low-density solid particle suspension;
- Method 3 is to dissolve the stabilizer in an organic solvent, uniformly spray the surface of the medical polyethylene or polypropylene material particles, granulate, and dry the solvent.
- a solid granule formulation was prepared which was dispersed into the hydrogel matrix prior to use to produce a suspension of low density solid particles having different CT density values.
- the aqueous matrix intestinal CT negative contrast agent prepared by the invention has good uniformity, stability and fluidity, and can effectively improve the clarity and contrast of the intestinal wall imaging.
- Low-density gas microbubbles or/and low-density solid particles are uniformly dispersed in the suspension, stable and non-layered; and have good fluidity and meet the requirements of perfusion.
- the isolated small intestine or the ratio CT imaging studies of the dog's rectal perfusion showed that the prepared CT negative contrast agent can greatly reduce the CT density value in the intestinal lumen to a range of 30HU to 200HU, because the CT density of the intestinal wall environment is 100 to 1 About 150 HU, therefore, the clarity, integrity and smoothness of the intestinal wall are much better than the control group with water as the contrast agent.
- the overall image of the intestine is uniform, and there is no signal difference caused by aggregation and stratification of low-density substance particles, further ensuring the reliability of diagnosis.
- the intestinal CT negative contrast agent prepared by the invention can simultaneously solve the problem of two-dimensional display of intestinal wall and three-dimensional image reconstruction in current intestinal CT imaging research, thereby greatly improving the sensitivity and specificity of diagnosis of intestinal wall and intestinal cavity diseases, especially It is of great significance for the early and accurate diagnosis of malignant tumors such as colon cancer.
- the prepared negative contrast agent is based on hydrogel, has good intestinal filling function, and can effectively avoid severe diarrhea caused by oil, fat, mannitol, etc.; low density gas microbubbles or/and low used
- the density solid particles have the characteristics of safety, no irritability, etc., and can effectively reduce the CT density value in the cavity after being infused into the intestinal lumen.
- the low-density contrast agent material is easily available, and the preparation method is simple and convenient, and is suitable for large-scale preparation. According to different observation requirements, the CT value of the negative contrast agent can be conveniently adjusted by adjusting the amount of low-density substance added to the matrix to obtain a good two-dimensional contrast image and three-dimensional reconstruction image of the intestinal wall.
- Example 1 The main component of the contrast agent was 20 °/ of medical polyethylene particles having an ultrafine pulverization and an average diameter of 200 ⁇ 1. 0%, The remainder is deionized water.
- the stabilizer is 5% of the mixture of pluronic F68 and sodium dodecyl sulfonate.
- the specific preparation method is as follows: Mixing commercially available polyethylene particles conforming to medical requirements with Pluronic F68 in a ratio of 100:1, adding to a jet mill, superfine pulverization, and obtaining a surface adsorbed with Pluronic F68. Polyethylene pellets with an average diameter of 200Mm.
- CT density value of contrast agent itself The prepared suspension was placed in a covered plastic test tube for CT scanning, and the CT density value was measured. The results showed that: in the control group, the CT density of water was still zero; the CT density of the prepared suspension negative shadow agent was 30HU, and there was no significant difference in CT density values at each scanning level, which could be within 20 minutes. Stay stable without delamination.
- Intestinal CT density was measured after intestine perfusion in vitro: The prepared CT intestine CT negative contrast agent was perfused into an isolated pig intestine to remove air and smear; The pig intestine was used as a control group. Two sections of isolated pig intestines were immersed in cooking oil or paraffin oil which simulates the intestinal extra-fat fat environment, and the gas interface effect interference was shielded. CT scan was performed to determine the CT density value in the intestinal lumen. The results showed that: the CT density of the intestine in the control group was about zero, and the intestinal wall was blurred; the negative contrast agent group prepared by the infusion was filled with a CT value of about 30 HU, and the intestinal wall showed obvious control group and intestinal image. Light and dark evenly.
- the 5%, a water-based substrate, the main component of the present invention is a medicinal polypropylene granules having a mean diameter of 10 m, prepared by a co-milling method, 50%, a stabilizer of a mixture of pluronic F68 and sodium dodecyl sulfonate. 0 ⁇ The sodium polyacrylate hydrogel 0. 005% and methyl cellulose gel 0. 03%, the rest is deionized water.
- the specific preparation method comprises the following steps: pre-freezing the medical polypropylene particles having a CT density value of about 200 HU and having a CT density of about 200 HU in a mass ratio of 100:1, and then adding to the grinder to carry out the air flow.
- the co-grinding was promoted to obtain polypropylene particles having a particle size of 10 Mm and having a hydrophilic surface. 5 ⁇
- 50 grams of polypropylene particles were added to the mortar, and added stabilizer 3.
- 5 grams (of which, sodium dodecyl sulfate 0.5 g, Pluron 3 g), mixed hook; 10 ml of each of 05% sodium polyacrylate and 0.3% methylcellulose hydrogel was added to the mortar, ground and mixed, and then deionized water was added to 100 g. Magnetically stir and mix further.
- the prepared polypropylene particle-hydrogel negative contrast agent was measured by the self-CT density value described in Example 1 and the post-infusion intestinal CT density value measurement method. The results showed that the CT contrast value of the prepared negative contrast agent was About 100HU; CT density in the intestinal lumen after perfusion is reduced by about 100HU. The bowel wall is clear, complete and smooth. The image of the intestine is uniform and there is no visible mass.
- the main component of the present invention is a medicinal polypropylene granules having an average diameter of ⁇ ⁇ , 35%, a mixture of the stabilizer, pluronic F68 and sodium dodecyl sulfonate, 4.8%, agar gel, 0.0000%, methyl fiber
- the hydrogel was 0.02%, and the rest was deionized water.
- the specific preparation method is as follows: 100 g of medical polypropylene particles having a CT density of about 100 HU and having a particle size of ⁇ after ultrafine pulverization are placed in a coating pan; and an appropriate concentration of 6% is added to the spray gun. Lonnick F68 ethanol solution, evenly sprayed on the surface of polypropylene particles.
- the sprayed polypropylene granules were taken out, dried at 60 ° C, and weighed to determine a surface Pluronic F68 concentration of 2%.
- the prepared pre-dispersed surfactant polypropylene particle-hydrogel negative contrast agent was measured by the self-CT density value described in Example 1 and the post-perfusion intestinal CT density value measurement method. The results showed that the prepared CT contrast density of the negative contrast agent was about 85 HU. After perfusion, the CT density in the intestinal lumen decreased by about 85 HU. The intestinal wall is clear, complete and smooth. The image of the intestine is uniform and there is no visible mass.
- the main component of the contrast agent is surface modified, medical polyethylene and polypropylene fine powder with an average diameter of 50mn 5%, stabilizer polyoxyethylene-polyoxypropylene block copolymer and lecithin mixture 2%, scutellaria
- the gelatin was 0.5%, and the rest was deionized water.
- the specific preparation method is as follows: The medical polyethylene and polypropylene particles are mixed with lecithin, polyoxyethylene-polyoxypropylene block copolymer in a ratio of 50:1:1, and added to a jet mill for ultrafine pulverization.
- a fine powder of a mixture of polyethylene and polypropylene having a CT density value of 1000 HU and an average particle diameter of 50 nm and having a surface-dispersed stabilizer was obtained.
- the prepared poly-B A negative contrast agent was tested for the mixture of ene and polypropylene.
- the CT density of the prepared negative contrast agent was about 200 HU; the CT density of the intestinal lumen decreased by about 200 HU after perfusion.
- the bowel wall is clear, complete and smooth.
- the image of the intestine is uniform and there is no visible mass.
- the agglomerate of the present invention is a surface modified, an average diameter of 500 nm of ethylene-propylene random copolymer fine powder 10%, a stabilizer of polyoxyethylene hydrogenated castor oil and Tween mixture 3%, gum arabic hydrogel 0. 2 %, the rest is deionized water.
- the specific preparation method is as follows: The ethylene-propylene random copolymer particles are mixed with polyoxyethylene hydrogenated castor oil and Tween 60 in a ratio of 100:1:1, and added to a jet mill for ultrafine pulverization.
- a fine powder of ethylene-propylene random copolymer having a CT density of 600 HU and an average particle diameter of 100 nm and having a surface-dispersed stabilizer polyoxyethylene hydrogenated castor oil and Tween was obtained.
- the prepared polypropylene monomethylcellulose hydrogel negative contrast agent was measured by the self-CT density value described in Example 1 and the post-infusion intestinal CT density value measurement method.
- the CT density of the prepared negative contrast agent was about 100 HU; the CT density of the intestinal lumen decreased by about 100 HU after perfusion.
- the bowel wall is clear, complete and smooth.
- the image of the intestine is uniform and there is no visible mass.
- the main component of the contrast agent is a surface-modified, ethylene-propylene block copolymer fine powder having an average diameter of 1 Mm, 40%, a stabilizer polyoxyethylene hydrogenated castor oil, a mixture of Tween and Span 5%, carboxymethyl fiber. 8%, the rest is deionized water.
- the specific preparation method is as follows: The ethylene-propylene block copolymer particles are mixed with polyoxyethylene hydrogenated castor oil, Tween and Span in a ratio of 100: 1: 2: 1, and added to a jet mill for ultrafine pulverization.
- An ethylene-propylene block copolymer fine powder having a CT density of 400 HU and an average particle diameter of 1 Mm and having a stabilizer dispersed thereon was obtained.
- the prepared polypropylene monomethylcellulose hydrogel negative contrast agent was measured. The results showed that the CT density of the prepared negative contrast agent was about 80 HU. After perfusion, the CT density in the intestinal lumen was reduced by about 80 HU.
- the bowel wall is clear, complete and smooth. The image of the intestine is uniform and there is no visible mass.
- the main component of the present invention is the air microbubble 20% (v / v), the stabilizer albumin and gluconolactone 0.1%, methyl cellulose hydrogel 0.4%,
- the agar hydrogel was 0.1%
- the gelatin hydrogel was 0. 05%
- the rest was deionized water.
- the formed gas microbubbles are kept stable by being combined with a stabilizer in the hydrogel matrix.
- the mixture of the present agent is a mixture of the stabilizers albumin, cetyltrimethylammonium bromide and polyoxyethylene-polyoxypropylene block copolymer 1. 55% 5%, The rest is deionized water. The 5%, the gelatin hydrogel is 0.5%. Nitrogen microbubbles formed by high speed agitation under aeration conditions are stabilized by binding to a stabilizer in the hydrogel matrix.
- the specific preparation method is as follows: Weighing stabilizer 1. 55 g (including albumin 1 g, cetyltrimethylammonium bromide 0. 05 g, Pluronic F68 0.
- the prepared nitrogen microbubble-hydrogel negative contrast agent was measured by the self-CT density value described in Example 1 and the post-infusion intestinal CT density value measurement method. The results show that the prepared CT contrast density of the negative contrast agent is a 500HU left. Right; CT density in the intestinal lumen after perfusion decreased by about 500 HU. The image of the intestine is uniform and there is no visible mass.
- the main component of the contrast agent is helium microbubble 5% (v/v), a mixture of stabilizer sodium dodecyl sulfate and pluronic F68 1%, methylcellulose hydrogel 0.4%, agar water
- the gel was 0.3%, and the rest was deionized water.
- the helium microbubbles formed by high-speed agitation under helium conditions are stabilized by being combined with a stabilizer in the hydrogel matrix.
- the 3% agar and 0. 3% agar are added to a solution containing 100% of the sodium sulfonate and 0.5% of the agarose. In the hydrogel, mix well.
- Example 10 The mixture was stirred for 3 minutes using a tissue homogenizer at a speed of 1000 rpm, and helium gas was introduced while stirring to obtain a milky white helium microbubble-hydrogel suspension.
- the prepared gas microbubble-hydrogel-negative contrast agent was measured by the self-CT density value described in Example 1 and the post-infusion intestinal CT density value measurement method. The results showed that the CT density of the prepared negative contrast agent was about -50 HU; the CT density of the intestinal lumen decreased by about 50 HU after perfusion. The image of the intestine is uniform and there is no visible mass. : Example 10
- the main component of the contrast agent is sulphur hexafluoride gas microbubbles 10% (v / v), stabilizer phosphorus, phosphatidic acid and pluronic F68 mixture 2%, methyl cellulose hydrogel 0. 3% , agar 7. gel 0.2%, the rest is deionized water.
- the sulfur hexafluoride microbubbles formed by heating and gasification remain stable by binding to a stabilizer in the hydrogel matrix.
- the styling solution is 0. 3% methylcellulose and 0. 2 Mix well in the % agar hydrogel.
- the mixture was cooled with an ice bath, and a sulfur hexafluoride liquid was added dropwise thereto, and stirred for 1 minute using a tissue homogenizer at a rotation speed of 1000 rpm to obtain an oil-in-water emulsion having sulfur hexafluoride as an oil phase.
- the emulsion was heated in a 25 ° C water bath to vaporize sulfur hexafluoride to form a gas microbubble, thereby obtaining a milky white sulfur hexafluoride gas microbubble-hydrogel suspension.
- the prepared gas microbubble-hydrogel negative contrast agent was measured by the self-CT density value described in Example 1 and the post-infusion intestinal CT density value measurement method.
- the image of the intestine is uniform and there is no visible mass.
- the main component of the contrast agent is trichlorofluoromethicone gas microbubbles 30% (v/v), stabilizer phosphatidylethanolamine, phosphatidic acid and pluronic F68 mixture 5%, sodium carboxymethyl cellulose hydrogel 0% 1%, agar hydrogel 0.1%, the rest is deionized water.
- the trichlorofluoromethane microbubbles formed by heating and gasification remain stable by binding to a stabilizer in the hydrogel matrix. ⁇ carboxymethylcellulose sodium is added.
- the prepared gas microbubble-hydrogel negative contrast agent was measured by the self-CT density value described in Example 1 and the post-infusion intestinal CT density value measurement method. The results showed that the CT density of the prepared negative contrast agent was about 400 HU; the CT density of the intestinal lumen decreased by about 400 HU after perfusion. The images of the intestine were hooked and there were no visible masses.
- the main component of the contrast agent is 20% (v/v) of microbubbles of mixed gas of dichlorofluoroethane and trichlorofluoromethicone, 3% mixture of stabilizer phospholipid, phosphatidylethanolamine and pluronic F68, Sodium acrylate hydrogel 0. 05%, agar hydrogel 0.1%, the rest is deionized water.
- the mixed gas microbubbles of dichlorofluoroethane and trichlorofluoromethane formed by heating and gasification are kept stable by being combined with a stabilizer in the hydrogel matrix.
- the sulphate is 0. 05% sodium polyacrylate and 0. 1%. Mix well in the % agar hydrogel.
- the gas microbubble-hydrogel negative contrast agent was measured. The results showed that the CT density of the prepared negative contrast agent was about 250 HU. The CT density of the intestinal lumen decreased by about 250 HU after perfusion. The image of the intestine is uniform and there is no visible mass.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/300,240 US8747812B2 (en) | 2006-05-11 | 2006-05-22 | Aqueous negative contrast medium for CT imaging of the gastrointestinal tract and the preparation method thereof |
EP06741951A EP2050470A1 (en) | 2006-05-11 | 2006-05-22 | Ct negative contrast medium of aqueous matrix for digestive tract and the preparation method thereof |
KR20087030173A KR101485501B1 (ko) | 2006-05-11 | 2006-05-22 | 위장관의 ct 영상용 수성 음성 조영제 및 그 제조 방법 |
JP2009508085A JP5174011B2 (ja) | 2006-05-11 | 2006-05-22 | 消化管のct撮像用の水性陰性造影剤およびその調製方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200610026434.4 | 2006-05-11 | ||
CNB2006100264344A CN100400105C (zh) | 2006-05-11 | 2006-05-11 | 水性基质的消化道ct阴性造影剂及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007131390A1 true WO2007131390A1 (fr) | 2007-11-22 |
Family
ID=37518392
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2006/001063 WO2007131390A1 (fr) | 2006-05-11 | 2006-05-22 | Milieu de contraste radiotransparent formé d'une matrice aqueuse pour la tomographie par ordinateur du tractus gastrointestinal et procédé de préparation de ce dernier |
Country Status (6)
Country | Link |
---|---|
US (1) | US8747812B2 (zh) |
EP (1) | EP2050470A1 (zh) |
JP (1) | JP5174011B2 (zh) |
KR (1) | KR101485501B1 (zh) |
CN (1) | CN100400105C (zh) |
WO (1) | WO2007131390A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018158195A1 (en) | 2017-02-28 | 2018-09-07 | Lument Ab | Per-oral negative contrast agent for abdominal ct |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2047843B1 (en) * | 2006-07-20 | 2016-08-03 | Kao Corporation | Hydrogel particle |
US8617892B2 (en) | 2009-09-01 | 2013-12-31 | The Trustees Of Columbia University In The City Of New York | Microbubble devices, methods and systems |
JP6463342B2 (ja) * | 2014-04-10 | 2019-01-30 | 国立大学法人 岡山大学 | 粘性気泡液の製造装置およびそれを用いた粘性気泡液の製造方法 |
ES2890328T3 (es) * | 2015-04-20 | 2022-01-18 | Univ California | Gas encapsulado o material de contraste de CT de vacío parcial |
CN109289095B (zh) * | 2018-11-23 | 2021-03-26 | 淮海工学院 | 一种含盐酸利多卡因的肠镜凝胶剂及其制备方法 |
DE112022002442T5 (de) * | 2021-05-06 | 2024-03-07 | Rigaku Corporation | Röntgen-kontrastmittel und röntgen-bilderfassungsverfahren |
CN115192736B (zh) * | 2022-08-22 | 2023-08-15 | 内蒙古爱众医学影像有限公司 | 一种煤制轻质白油纳米乳型低密度造影剂及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1233505A (zh) * | 1998-04-24 | 1999-11-03 | 胡挽华 | 一种胃肠阴性造影剂及其生产方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5562099A (en) * | 1990-10-05 | 1996-10-08 | Massachusetts Institute Of Technology | Polymeric microparticles containing agents for imaging |
US5205290A (en) * | 1991-04-05 | 1993-04-27 | Unger Evan C | Low density microspheres and their use as contrast agents for computed tomography |
US5874062A (en) * | 1991-04-05 | 1999-02-23 | Imarx Pharmaceutical Corp. | Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents |
CN1035661C (zh) * | 1994-02-07 | 1997-08-20 | 中国人民解放军兰州军区乌鲁木齐总医院 | 低密度造影剂 |
US5736121A (en) * | 1994-05-23 | 1998-04-07 | Imarx Pharmaceutical Corp. | Stabilized homogenous suspensions as computed tomography contrast agents |
PL332820A1 (en) * | 1996-10-21 | 1999-10-11 | Nycomed Imaging As | Improved contrast media |
AUPQ605500A0 (en) * | 2000-03-07 | 2000-03-30 | Medefield Pty Ltd | Stool marker |
CN1162186C (zh) * | 2000-08-01 | 2004-08-18 | 阿都沁夫 | 低密度胃肠用造影剂及生产方法 |
CN1159065C (zh) * | 2001-11-19 | 2004-07-28 | 侯书君 | 一种螺旋ct三维仿真内镜造影剂及其生产方法 |
-
2006
- 2006-05-11 CN CNB2006100264344A patent/CN100400105C/zh not_active Expired - Fee Related
- 2006-05-22 KR KR20087030173A patent/KR101485501B1/ko not_active IP Right Cessation
- 2006-05-22 WO PCT/CN2006/001063 patent/WO2007131390A1/zh active Application Filing
- 2006-05-22 EP EP06741951A patent/EP2050470A1/en not_active Withdrawn
- 2006-05-22 JP JP2009508085A patent/JP5174011B2/ja not_active Expired - Fee Related
- 2006-05-22 US US12/300,240 patent/US8747812B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1233505A (zh) * | 1998-04-24 | 1999-11-03 | 胡挽华 | 一种胃肠阴性造影剂及其生产方法 |
Non-Patent Citations (2)
Title |
---|
DING WEI ET AL.: "The Prospective Study on a Contrast Medium Eliminating Artifact Produced by Endogastric Fluid Level in CT Scan", JOURNAL OF PRACTICAL RADIOLOGY (CHINESE), vol. 13, no. 3, March 1997 (1997-03-01), pages 146 - 148, XP008102512 * |
DOERFLER OC; RUPPERT-KOHLMAYR AJ; REITTNER P ET AL., ABDOMINAL IMAGING, vol. 28, no. 3, 2003, pages 313 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018158195A1 (en) | 2017-02-28 | 2018-09-07 | Lument Ab | Per-oral negative contrast agent for abdominal ct |
EP3900744A1 (en) | 2017-02-28 | 2021-10-27 | Lument AB | Powder for per-oral negative contrast agent |
Also Published As
Publication number | Publication date |
---|---|
EP2050470A1 (en) | 2009-04-22 |
CN1879895A (zh) | 2006-12-20 |
US8747812B2 (en) | 2014-06-10 |
US20100166668A1 (en) | 2010-07-01 |
JP2009536624A (ja) | 2009-10-15 |
KR101485501B1 (ko) | 2015-01-22 |
KR20090025230A (ko) | 2009-03-10 |
CN100400105C (zh) | 2008-07-09 |
JP5174011B2 (ja) | 2013-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007131390A1 (fr) | Milieu de contraste radiotransparent formé d'une matrice aqueuse pour la tomographie par ordinateur du tractus gastrointestinal et procédé de préparation de ce dernier | |
DK171526B1 (da) | Anvendelse af ferromagnetiske partikler til fremstilling af et partikkelformigt diagnostisk kontrastmiddel til NMR-billeddannelse | |
Shi et al. | A smart all-in-one theranostic platform for CT imaging guided tumor microwave thermotherapy based on IL@ ZrO 2 nanoparticles | |
Rajinikanth | Preparation and characterization of gellan based floating beads of acetohydroxamic acid for eradication of | |
JP2009508924A (ja) | シリコンを含む造影剤 | |
JPH10502341A (ja) | 微小結晶製剤用の安定剤被膜としてのブチレンオキサイド−エチレンオキサイドブロック共重合体界面活性剤 | |
Chen et al. | Double-sided effect of tumor microenvironment on platelets targeting nanoparticles | |
TW200900082A (en) | Drug release from thermosensitive liposomes by applying an alternative magnetic field | |
Huang et al. | Synthesis and characterization of Bi2S3 composite nanoparticles with high X-ray absorption | |
Wang et al. | Gadolinium-loaded solid lipid nanoparticles for colorectal tumor in MR colonography | |
JP2000504742A (ja) | コントラスト媒体 | |
Ma et al. | Three-dimensional angiography fused with CT/MRI for multimodal imaging of nanoparticles based on Ba 4 Yb 3 F 17: Lu 3+, Gd 3+ | |
Shakeri et al. | Hyaluronic acid-coated ultrasmall BiOI nanoparticles as a potentially targeted contrast agent for X-ray computed tomography | |
CN105664188A (zh) | 一种子宫输卵管腔道超声造影剂及其制备方法 | |
WO2024077903A1 (zh) | 一种双组份胃部超声检查助显剂及其制备方法 | |
CN115531411B (zh) | 一种具备ct成像和治疗双重作用的药物及其制备方法和应用 | |
Zhan et al. | Silica cross-linked micellar core–shell nanoparticles encapsulating IR-780 with strong bright and good biocompatibility for optical imaging in vivo | |
WO1994011033A1 (en) | Granular preparation for mri | |
CN109453395A (zh) | 超稳定单分散的荧光磁性诊疗纳米探针及其制备方法和应用 | |
Zhang et al. | Nanobubbles loaded with carbon quantum dots for ultrasonic fluorescence dual detection | |
BR102016016795A2 (pt) | Nanopartículas lipídicas sólidas magnéticas a base de cera de carnaúba com potencial aplicação em hipertermia magnética e imagem por ressonância magnética | |
CN115120747B (zh) | 一种羟基磷灰石负载的四氧化三铁纳米棒及其制备方法和应用 | |
JP2019510759A (ja) | イメージングのためのビーズの調製のための方法 | |
Hu et al. | Preparation of lipid nano-bubbles as contrast agent material for tumor ultrasound diagnosis of breast cancer | |
CN106139168A (zh) | 具有脑神经胶质瘤靶向功能的氢氧化钆纳米棒的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 06741951 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009508085 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12300240 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006741951 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087030173 Country of ref document: KR |